Bicara Therapeutics
Clinical trials sponsored by Bicara Therapeutics, explained in plain language.
Clinical-stage biotech developing bifunctional antibodies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Can a new drug combo slow advanced head and neck cancer?
Disease control Recruiting nowThis phase 2 trial tests an experimental drug called ficerafusp alfa, which targets two proteins that help tumors grow, when given with the immunotherapy pembrolizumab. The study enrolls adults with recurrent or metastatic head and neck squamous cell carcinoma that has not been t…
Phase 2 • Sponsor: Bicara Therapeutics • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New combo therapy aims to shrink head and neck tumors that resist standard treatment
Disease control Recruiting nowThis study tests whether adding an experimental drug called ficerafusp alfa to the immunotherapy pembrolizumab (Keytruda) works better than pembrolizumab alone for people with PD-L1-positive head and neck cancer that has spread or returned. About 650 adults will be randomly assig…
Phase 2/3 • Sponsor: Bicara Therapeutics • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC